A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer

Ikuo Sekine, John D. Minna, Kazuto Nishio, Tomohide Tamura, Nagahiro Saijo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: To find candidate genes for a predictive chemosensitivity test in patients with lung cancer by using a literature review. METHODS: Using MEDLINE searches, "in vitro chemosensitivity associated genes" and articles on association of the gene alteration with clinical chemosensitivity in lung cancer patients were selected. We calculated odds ratios (ORs) and their 95% confidence intervals (95% CIs) of response rates for patients who had tumors with or without gene alteration. Combined ORs and 95% CIs were estimated using the DerSimonian-Laird method. RESULTS: Of the 80 in vitro chemosensitivity- associated genes identified, 13 genes were evaluated for association with clinical chemosensitivity in 27 studies. The median (range) number of patients in each study was 50 (range, 28-108). The response rates of lung cancer with high and low P-glycoprotein expression were 0% and 73% to 85%, respectively (p < 0.001). Glutathione S-transferase pi expression (OR 0.22, 95% CI 0.06-0.79), excision repair cross-complementing 1 alterations (combined OR 0.53, 95% CI 0.28-1.01; p = 0.055), and tumor suppressor p53 mutation (combined OR 0.25, 95% CI 0.12-0.52) were associated with clinical chemosensitivity. CONCLUSION: In total, 80 in vitro chemosensitivity-associated genes were identified in the literature, and high and low P-glycoprotein, glutathione S-transferase pi expression, excision repair cross-complementing 1 alterations, and tumor suppressor p53 mutation were candidates for future clinical trials of chemosensitivity tests in lung cancer patients.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalJournal of Thoracic Oncology
Volume1
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Lung Neoplasms
Biomarkers
Drug Therapy
Odds Ratio
Confidence Intervals
Genes
Glutathione S-Transferase pi
Genetic Suppression
P-Glycoprotein
DNA Repair
Neoplasms
MEDLINE
Clinical Trials
In Vitro Techniques

Keywords

  • Chemotherapy
  • Drug response
  • Lung cancer
  • Molecular markers
  • Prediction

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. / Sekine, Ikuo; Minna, John D.; Nishio, Kazuto; Tamura, Tomohide; Saijo, Nagahiro.

In: Journal of Thoracic Oncology, Vol. 1, No. 1, 01.2006, p. 31-37.

Research output: Contribution to journalArticle

@article{709cbbaf3a3e4307943a835682a98cb1,
title = "A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer",
abstract = "BACKGROUND: To find candidate genes for a predictive chemosensitivity test in patients with lung cancer by using a literature review. METHODS: Using MEDLINE searches, {"}in vitro chemosensitivity associated genes{"} and articles on association of the gene alteration with clinical chemosensitivity in lung cancer patients were selected. We calculated odds ratios (ORs) and their 95{\%} confidence intervals (95{\%} CIs) of response rates for patients who had tumors with or without gene alteration. Combined ORs and 95{\%} CIs were estimated using the DerSimonian-Laird method. RESULTS: Of the 80 in vitro chemosensitivity- associated genes identified, 13 genes were evaluated for association with clinical chemosensitivity in 27 studies. The median (range) number of patients in each study was 50 (range, 28-108). The response rates of lung cancer with high and low P-glycoprotein expression were 0{\%} and 73{\%} to 85{\%}, respectively (p < 0.001). Glutathione S-transferase pi expression (OR 0.22, 95{\%} CI 0.06-0.79), excision repair cross-complementing 1 alterations (combined OR 0.53, 95{\%} CI 0.28-1.01; p = 0.055), and tumor suppressor p53 mutation (combined OR 0.25, 95{\%} CI 0.12-0.52) were associated with clinical chemosensitivity. CONCLUSION: In total, 80 in vitro chemosensitivity-associated genes were identified in the literature, and high and low P-glycoprotein, glutathione S-transferase pi expression, excision repair cross-complementing 1 alterations, and tumor suppressor p53 mutation were candidates for future clinical trials of chemosensitivity tests in lung cancer patients.",
keywords = "Chemotherapy, Drug response, Lung cancer, Molecular markers, Prediction",
author = "Ikuo Sekine and Minna, {John D.} and Kazuto Nishio and Tomohide Tamura and Nagahiro Saijo",
year = "2006",
month = "1",
doi = "10.1097/01243894-200601000-00008",
language = "English (US)",
volume = "1",
pages = "31--37",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

TY - JOUR

T1 - A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer

AU - Sekine, Ikuo

AU - Minna, John D.

AU - Nishio, Kazuto

AU - Tamura, Tomohide

AU - Saijo, Nagahiro

PY - 2006/1

Y1 - 2006/1

N2 - BACKGROUND: To find candidate genes for a predictive chemosensitivity test in patients with lung cancer by using a literature review. METHODS: Using MEDLINE searches, "in vitro chemosensitivity associated genes" and articles on association of the gene alteration with clinical chemosensitivity in lung cancer patients were selected. We calculated odds ratios (ORs) and their 95% confidence intervals (95% CIs) of response rates for patients who had tumors with or without gene alteration. Combined ORs and 95% CIs were estimated using the DerSimonian-Laird method. RESULTS: Of the 80 in vitro chemosensitivity- associated genes identified, 13 genes were evaluated for association with clinical chemosensitivity in 27 studies. The median (range) number of patients in each study was 50 (range, 28-108). The response rates of lung cancer with high and low P-glycoprotein expression were 0% and 73% to 85%, respectively (p < 0.001). Glutathione S-transferase pi expression (OR 0.22, 95% CI 0.06-0.79), excision repair cross-complementing 1 alterations (combined OR 0.53, 95% CI 0.28-1.01; p = 0.055), and tumor suppressor p53 mutation (combined OR 0.25, 95% CI 0.12-0.52) were associated with clinical chemosensitivity. CONCLUSION: In total, 80 in vitro chemosensitivity-associated genes were identified in the literature, and high and low P-glycoprotein, glutathione S-transferase pi expression, excision repair cross-complementing 1 alterations, and tumor suppressor p53 mutation were candidates for future clinical trials of chemosensitivity tests in lung cancer patients.

AB - BACKGROUND: To find candidate genes for a predictive chemosensitivity test in patients with lung cancer by using a literature review. METHODS: Using MEDLINE searches, "in vitro chemosensitivity associated genes" and articles on association of the gene alteration with clinical chemosensitivity in lung cancer patients were selected. We calculated odds ratios (ORs) and their 95% confidence intervals (95% CIs) of response rates for patients who had tumors with or without gene alteration. Combined ORs and 95% CIs were estimated using the DerSimonian-Laird method. RESULTS: Of the 80 in vitro chemosensitivity- associated genes identified, 13 genes were evaluated for association with clinical chemosensitivity in 27 studies. The median (range) number of patients in each study was 50 (range, 28-108). The response rates of lung cancer with high and low P-glycoprotein expression were 0% and 73% to 85%, respectively (p < 0.001). Glutathione S-transferase pi expression (OR 0.22, 95% CI 0.06-0.79), excision repair cross-complementing 1 alterations (combined OR 0.53, 95% CI 0.28-1.01; p = 0.055), and tumor suppressor p53 mutation (combined OR 0.25, 95% CI 0.12-0.52) were associated with clinical chemosensitivity. CONCLUSION: In total, 80 in vitro chemosensitivity-associated genes were identified in the literature, and high and low P-glycoprotein, glutathione S-transferase pi expression, excision repair cross-complementing 1 alterations, and tumor suppressor p53 mutation were candidates for future clinical trials of chemosensitivity tests in lung cancer patients.

KW - Chemotherapy

KW - Drug response

KW - Lung cancer

KW - Molecular markers

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=33947600789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947600789&partnerID=8YFLogxK

U2 - 10.1097/01243894-200601000-00008

DO - 10.1097/01243894-200601000-00008

M3 - Article

C2 - 17409824

AN - SCOPUS:33947600789

VL - 1

SP - 31

EP - 37

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -